View all IQVIA events
A review of the prescription medicines market in the EU4, UK, US, and Japan through Q3 2022, and a deep dive primary research study into the ongoing impact of the pandemic on patient care in cancer
In this webinar, IQVIA experts cover two key topics. First, we take stock of recent prescription (Rx) medicine market trends to Q3 of 2022 with a view on 2023. In this section, we will:- Examine the current status of global COVID-19 vaccination and treatments as we enter the winter season
- Assess long term and recent post Pandemic trends in Rx markets of key countries: US, Japan, UK, Germany, France, Italy, Spain, with a focus on key therapeutic markets
- Share the latest updates on innovative launch performance across these countries
Next, we’ll share the results of our latest primary research in Oncology, now the world’s most important Rx medicine market. With severe disruption to cancer patients’ care due to the Pandemic, our experts also reveal the latest results of our ongoing primary research series with oncologists and haematologists across the EU4, UK and US. We explore how their workload and their engagement with patients continues to evolve, and how cancer patient care, in all its aspects, has changed. Finally, we’ll discuss the unmet needs in patient care and doctors’ perception of how pharmaceutical companies can support.